UnknownPhase 4NCT02550080

Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

Studying Cutaneous small vessel vasculitis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shandong Provincial Institute of Dermatology and Venereology
Principal Investigator
Furen Zhang
Shandong Provincial Institute of Dermatology and Venereology
Intervention
Dapsone(drug)
Enrollment
3130 enrolled
Eligibility
18-65 years · All sexes
Timeline
2015 – 2019

Study locations (1)

Collaborators

Shandong Provincial Hospital · Jinan Central Hospital · Shandong Qianfo Hospital · Jinan Military General Hospital · Qingdao Hiser Medical Group · Liaocheng People's Hospital · Dongying People's Hospital · Jining First People's Hospital · Dezhou People's Hospital · Jinan City Dermatology Hospital Prevention and Treatment · Linyi City Dermatology Hospital Prevention and Treatment · Jining City Dermatology Hospital Prevention and Treatment · Weifang City Dermatology Hospital Prevention and Treatment · Laiwu City Dermatology Hospital Prevention and Treatment · Rizhao City Dermatology Hospital Prevention and Treatment

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02550080 on ClinicalTrials.gov
← Back to all trials